Lupus Science & Medicine® is a global, peer reviewed, open access online journal that provides a central point for publication of basic, clinical, translational, and epidemiological studies of all …

A lupus journal publishing basic, clinical, translational and epidemiological studies on all aspects of lupus and related diseases. An official journal of Lupus Foundation of America.

2025年1月4日 · Objective Black people in the USA have a higher incidence and severity of SLE and worse outcomes, yet they are significantly under-represented in SLE clinical trials. We …

2024年11月19日 · Methods This study was designed to retrospectively analyse patients with SLE treated with 2 g/kg/month of intravenous IG (divided across 5 consecutive days). We collected …

2024年10月13日 · Objective This study aimed to validate claims-based algorithms for identifying SLE and lupus nephritis (LN) in Medicare data, enhancing the use of the Lupus Index for …

2025年1月6日 · Objective Both belimumab and telitacicept are recognised blockers for B lymphocyte activation, both of which have been approved as add-on therapies for SLE in …

Lupus Science & Medicine® is a global, peer reviewed, open access, online journal that provides a central point for publication of basic, clinical, translational, and epidemiological studies of all …

2024年5月22日 · Our 2022 published working definition of disease modification in systemic lupus erythematosus (SLE) was ‘minimising disease activity with the fewest treatment-associated …

AskanasefiAD, etfial Lupus Science Medicine 202411:e001124 doi:101136lupus-2023-001124 1 Disease- modifying therapies in systemic lupus erythematosus for extrarenal manifestations …

2024年9月4日 · Systemic lupus erythematosus (SLE) is associated with a wide variety of ocular manifestations. Some of these include uveitis, occlusive retinal vasculitis, (epi)scleritis and …